© 2024 MJH Life Sciences™ and Center for Biosimilars®. All rights reserved.
Latest Conference Articles
Researchers Report on Infliximab Biosimilars BCD-055 and CT-P13
Kelly Davio
June 14 2018
At the European League Against Rheumatism (EULAR)'s Annual European Congress of Rheumatology, held from June 13-16 in Amsterdam, Netherlands, researchers reported on Biocad’s Russian-authorized biosimilar infliximab, BCD-055, and on switches to the widely approved infliximab biosimilar CT-P13 (Inflectra, Remsima).
Once Educated, Patients Generally Receptive to Switching to Biosimilars
Kelly Davio
June 13 2018
At the European League Against Rheumatism’s Annual European Congress of Rheumatology, held from June 13-16 in Amsterdam, Netherlands, the patient experience with switching to biosimilars from their reference products is a key topic among stakeholders.
Nonmedical Switches Reduce Treatment Costs, Increase Healthcare Utilization
Kelly Davio
June 13 2018
During the European League Against Rheumatism’s Annual European Congress of Rheumatology, researchers published findings on the economic impacts of nonmedical switching; while 1 study found that switching to biosimilar infliximab brought down costs without sacrificing efficacy or safety, but another raised concerns about increases in overall healthcare utilization.
New Directions in Oncology Biosimilars
Jaime Rosenberg
June 8 2018
During a session at the 2018 American Society of Clinical Oncology Annual Meeting, held June 1-5 in Chicago, Illinois, researchers gave a glimpse into new directions in oncology biosimilars through providing results on several studies testing the safety, efficacy, and usage of different biosimilars.
Research Reports on Rituximab in Treating MCL and DLBCL
Kelly Davio
June 7 2018
During the 2018 American Society of Clinical Oncology Annual Meeting, researchers published new findings on the use of rituximab in mantle cell lymphoma (MCL) as well as the outcomes of patients who relapse early after treatment with rituximab for diffuse large B-cell lymphoma (DLBCL).
Similar PK, Safety, and Immunogenicity Demonstrated for Proposed Bevacizumab Biosimilar
Samantha DiGrande
June 6 2018
The proposed biosimilar, TAB008, under development by TOT Biopharm, was compared with the reference bevacizumab in a randomized, double-blind, single-dose study conducted in 99 healthy adult males.
Real-World Evidence Shows Benefits of On-Body Pegfilgrastim, But Low Use of G-CSF Agents
Kelly Davio
June 6 2018
Clinical practice guidelines recommend the use of granulocyte-colony stimulating factor (G-CSF) therapies, including the long-acting pegfilgrastim (Neulasta), for the prevention of febrile neutropenia in patients receiving myelosuppressive chemotherapy. Real-world data, published in an abstract concurrent with the 2018 American Society of Clinical Oncology Annual Meeting, demonstrate the feasibility of administering pegfilgrastim via an on-body device.
Biosimilar, Follow-On Filgrastim Feature in New Research on FN and Peripheral Stem Cell Mobilization
Kelly Davio
June 5 2018
Research published in conjunction with the 2018 American Society of Clinical Oncology Annual Meeting presented new findings on the use granulocyte-colony stimulating factor agents in treating febrile neutropenia (FN) and in peripheral stem cell mobilization.
7 Biosimilars Takeaways from ISPOR 2018
The Center for Biosimilars Staff
May 27 2018
At the International Society for Pharmacoeconomics and Outcomes Research’s (ISPOR) 23rd Annual International Meeting in Baltimore, Maryland, researchers and speakers highlighted emerging trends in biosimilars. Here are 7 key takeaways from the conference.